Clinical Trial: QLS4131 Plus Isatuximab in Newly Diagnosed Primary Plasma Cell Leukemia

U.S., Oct. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07903623) titled 'QLS4131 Plus Isatuximab in Newly Diagnosed Primary Plasma Cell Leukemia' on Oct. 23.

Brief Summary: The goal of this clinical trial is to learn whether QLS4131, a BCMA/GPRC5D/CD3 trispecific antibody, can improve treatment outcomes when combined with isatuximab in adults with newly diagnosed primary plasma cell leukemia (pPCL). The study will also evaluate the safety of this treatment combination.

The main questions it aims to answer are:

* How many participants achieve measurable residual disease (MRD) negativity after 9 treatment cycles?

* What side effects occur during treatment with QLS4131 combined with isatuximab?

* How ma...